PACS Group
PACS Group's revenue rose 29.3% to $5.3 billion in fiscal 2025. Its operating margin was 5.8%, up from 3.0% a year earlier. Free cash flow was $299 million, down 0.7%. The diluted share count rose 5.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What PACS Group does
PACS Group runs skilled nursing facilities in the United States. These provide round-the-clock care to people who have left the hospital but still need help recovering, and some also offer long-term care. It also provides assisted living and independent living in some of its communities. It operates 321 post-acute care facilities in 17 states, serving over 31,700 patients a day.
PACS was founded in 2013. It says it has grown mainly by buying skilled nursing facilities that focus on long-term custodial care and turning them into facilities for short-term transitional care. It says it gives each facility local leaders who run it independently, with technology, support and back-office services from the center. It reports a single segment and earns revenue mainly from Medicare, Medicaid and other payors.
The 10-K says a short-seller report was published about the company in November 2024. An audit committee investigation found material weaknesses in internal control over financial reporting and led to a restatement of two quarters of financial statements. The company and some executives face a securities class action, and the company has received subpoenas from the Department of Justice.
Its biggest risks, as it describes them
- Its revenue depends on payments from Medicare, Medicaid and other payors, and changes in those could hurt it.
- A short-seller report led to restated results, weaknesses in controls, lawsuits and government investigations.
- A shortage of nurses and other staff could raise its labor costs.
- Providing poor quality of care could hurt its patients and its business.
- It may not be able to buy more facilities at good prices.
Income statement
From fiscal 2022 to 2025, earnings per share grew 1.4% a year and net income 8.4% a year, as new shares raised the share count by 22% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | 58 | 73 | 158 | 197 |
| Debt incl. finance leases | — | 254 | 559 | 509 |
| Net debt (negative means net cash) | — | 181 | 401 | 312 |
| Net debt to EBITDA | — | — | — | — |
| Debt to equity | — | — | 0.8x | 0.5x |
| Interest coverage | 9.0x | 4.2x | 2.8x | 10.9x |
| Current ratio | — | 1.6x | 1.0x | 1.1x |
| Quick ratio | — | 1.6x | 1.0x | 1.1x |
Cash flow
Projections
Project PACS Group's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What PACS Group says to expect
- Full year 2026: revenue
We are also increasing our revenue guidance to $5.95 billion to $6.05 billion, up from our prior range of $5.75 billion to $5.85 billion.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $500,048 of PACS Group shares on the open market, and 6 insiders sold $79.9 million, $73.7 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Joshua JergensenPresident & COO | Sold plan | 40,000 | $43.13 | $1.7 million | Form 4 |
| Sep 15, 2026 | Mark HancockDirector, 10% owner | Sold plan | 155,682 | $42.47 | $6.6 million | Form 4 |
| Sep 14, 2026 | Mark HancockDirector, 10% owner | Sold plan | 144,318 | $44.58 | $6.4 million | Form 4 |
| Sep 14, 2026 | Jason Hulse MurrayCo-Founder, CEO & Chairman, Director, 10% owner | Sold plan | 317 | $45.03 | $14,275 | Form 4 |
| Sep 11, 2026 | Jason Hulse MurrayCo-Founder, CEO & Chairman, Director, 10% owner | Sold plan | 10,529 | $45.23 | $476,227 | Form 4 |
| Sep 10, 2026 | Jason Hulse MurrayCo-Founder, CEO & Chairman, Director, 10% owner | Sold plan | 8,771 | $45.16 | $396,098 | Form 4 |
| Sep 9, 2026 | Jason Hulse MurrayCo-Founder, CEO & Chairman, Director, 10% owner | Sold plan | 4,758 | $43.33 | $206,164 | Form 4 |
| Sep 8, 2026 | Jason Hulse MurrayCo-Founder, CEO & Chairman, Director, 10% owner | Sold plan | 24,057 | $43.49 | $1.0 million | Form 4 |
| Sep 4, 2026 | Jason Hulse MurrayCo-Founder, CEO & Chairman, Director, 10% owner | Sold plan | 23,072 | $42.68 | $984,825 | Form 4 |
| Sep 3, 2026 | Jason Hulse MurrayCo-Founder, CEO & Chairman, Director, 10% owner | Sold plan | 20,173 | $42.55 | $858,455 | Form 4 |
| Sep 2, 2026 | Jason Hulse MurrayCo-Founder, CEO & Chairman, Director, 10% owner | Sold plan | 23,783 | $42.93 | $1.0 million | Form 4 |
| Sep 1, 2026 | Jason Hulse MurrayCo-Founder, CEO & Chairman, Director, 10% owner | Sold plan | 24,157 | $42.39 | $1.0 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | 6 of 8 |
| Rule of 40 | 29.0% | 38.8% | 35.0% |
| Altman Z'' | 1.01 | 0.35 | 0.85 |
| Accruals ratio | — | −7.1% | −3.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | — | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | — | — | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | Pass |
| Current ratio rose | — | Fail | Pass |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | Fail |
| F-score | — | — | 6 of 8 |
Compare
Put PACS Group side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| PACS Group | FY25 | 29.3% | 5.8% | 5.7% | 17.5% | — | 6 | |
| Ensign Group | FY25 | 18.7% | 8.4% | — | 19.7% | −0.8x | 6 | Compare |
| Option Care Health | FY25 | 13.0% | 6.0% | 3.8% | 11.4% | 2.3x | 5 | Compare |
| Encompass Health | FY25 | 10.5% | — | 7.4% | 15.8% | 1.7x | 8 | Compare |
| Acadia Healthcare | FY25 | 5.0% | — | −13.3% | −16.0% | — | 4 | Compare |
4 years of figures
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 2,422 | 3,112 | 4,090 | 5,289 |
| Revenue growth | — | 28.5% | 31.4% | 29.3% |
| Gross profit | — | — | — | — |
| Research and development | — | — | — | — |
| Operating income | 229 | 208 | 123 | 310 |
| Net income | 150 | 113 | 56 | 192 |
| Diluted EPS (US$) | 1.17 | 0.88 | 0.38 | 1.22 |
| Diluted shares (millions) | 129 | 129 | 149 | 157 |
| Cash flow | ||||
| Cash from operations | 93 | 64 | 367 | 404 |
| Capital expenditure | 23 | 46 | 66 | 105 |
| Free cash flow | 70 | 18 | 301 | 299 |
| Dividends paid | 60 | 80 | 34 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 116 | 54 |
| Balance sheet at fiscal year end | ||||
| Cash and short-term investments | 58 | 73 | 158 | 197 |
| Debt incl. finance leases | — | 254 | 559 | 509 |
| Total assets | — | 3,513 | 5,243 | 5,584 |
| Total liabilities | — | 3,411 | 4,527 | 4,632 |
| Shareholders' equity | 69 | 96 | 710 | 947 |
| Margins and ratios | ||||
| Gross margin | — | — | — | — |
| Operating margin | 9.5% | 6.7% | 3.0% | 5.8% |
| Net margin | 6.2% | 3.6% | 1.4% | 3.6% |
| Free cash flow margin | 2.9% | 0.6% | 7.4% | 5.7% |
| Rule of 40 (growth + FCF margin) | — | 29.0% | 38.8% | 35.0% |
| Return on capital | — | — | 9.6% | 17.5% |
| Return on equity | — | — | 13.8% | 23.1% |
| Return on assets | — | — | 1.3% | 3.5% |
| Net debt to EBITDA | — | — | — | — |